Emergent BioSolutions received a $21.5 million order from the U.S. Department of War for BioThrax® vaccine deliveries in 2026.
Quiver AI Summary
Emergent BioSolutions announced a delivery order worth up to $21.5 million from the U.S. Department of War to provide its Anthrax vaccine, BioThrax®, in 2026. This order, which falls under an indefinite-delivery/indefinite-quantity contract, aims to protect military personnel at high risk of anthrax exposure. The delivery will occur in 2026, with options for continuation in 2027 and 2028. BioThrax® is approved for pre- and post-exposure prophylaxis against Bacillus anthracis and is indicated for individuals aged 18 to 65. Emergent's mission focuses on safeguarding public health by preparing against various health threats, including anthrax.
Potential Positives
- Emergent BioSolutions received a substantial delivery order valued at up to $21.5 million from the U.S. Department of War, indicating strong government trust and ongoing partnerships.
- The order is part of an existing indefinite-delivery/indefinite-quantity contract, ensuring continued business and potential future revenues through option periods in 2027 and 2028.
- Supplying BioThrax® supports the mission to protect U.S. service members, reinforcing the company's commitment to public health and safety.
- The press release highlights Emergent's long history in delivering life-saving solutions, showcasing its expertise and reputation within the industry.
Potential Negatives
- The efficacy of BioThrax® for post-exposure prophylaxis is based solely on studies in animal models, which may raise concerns about its effectiveness in humans.
- The safety information includes potential severe allergic reactions and other adverse effects, which could deter some customers or clients from using the product.
- There is a disclaimer stating that the views expressed do not constitute endorsement by the United States government, which could imply a lack of confidence from a highly authoritative entity.
FAQ
What is the value of Emergent BioSolutions' recent order from the U.S. Department of War?
The order is valued at up to $21.5 million for the supply of BioThrax® in 2026.
What is BioThrax® used for?
BioThrax® is used for the active immunization against diseases caused by Bacillus anthracis in persons aged 18 to 65.
When will deliveries of BioThrax® take place?
Deliveries under this order will occur in 2026, with potential option periods extending to 2027 and 2028.
Who is Emergent BioSolutions collaborating with for this contract?
Emergent is collaborating with the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense and the Defense Health Agency.
What are common adverse reactions to BioThrax®?
Common local reactions include tenderness and pain, while systemic reactions may include muscle aches and fatigue.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- COLEEN GLESSNER (EVP, Quality & Ethics, and CPL) sold 30,608 shares for an estimated $306,080
- RONALD RICHARD has made 0 purchases and 2 sales selling 21,984 shares for an estimated $263,077.
- DONALD W DEGOLYER has made 0 purchases and 2 sales selling 25,645 shares for an estimated $255,453.
- SUJATA TYAGI DAYAL sold 8,552 shares for an estimated $85,520
- KATHRYN C ZOON sold 7,086 shares for an estimated $62,852
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EBS Revenue
$EBS had revenues of $9.1M in Q3 2025. This is a decrease of -9.0% from the same period in the prior year.
You can track EBS financials on Quiver Quantitative's EBS stock page.
$EBS Hedge Fund Activity
We have seen 85 institutional investors add shares of $EBS stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 705,004 shares (+40.5%) to their portfolio in Q3 2025, for an estimated $6,218,135
- MILLENNIUM MANAGEMENT LLC removed 677,608 shares (-89.7%) from their portfolio in Q3 2025, for an estimated $5,976,502
- AQR CAPITAL MANAGEMENT LLC added 586,246 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,170,689
- JAIN GLOBAL LLC added 508,707 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,486,795
- PALISADE CAPITAL MANAGEMENT, LP added 326,260 shares (+29.7%) to their portfolio in Q3 2025, for an estimated $2,877,613
- DIMENSIONAL FUND ADVISORS LP added 291,308 shares (+15.8%) to their portfolio in Q3 2025, for an estimated $2,569,336
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 276,566 shares (+25.0%) to their portfolio in Q3 2025, for an estimated $2,439,312
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/16/2025
To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.
Full Release
GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax ® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency.
“As part of our mission to protect and save lives, we’re proud to help protect those who protect us, including our nation’s service members,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. “We’re pleased to continue our partnership with the U.S. Department of War to supply BioThrax ® to prepare military personnel at high risk of anthrax exposure.”
Deliveries under this order will take place in 2026. This order includes a one-year base period, with two additional option periods for 2027 and 2028.
About BioThrax
®
(Anthrax Vaccine Adsorbed)
BioThrax
®
vaccine is indicated for the active immunization for the prevention of disease caused by
Bacillus anthracis
in persons 18 through 65 years of age. BioThrax
®
is approved for (1) pre-exposure prophylaxis of disease in persons at high risk of exposure; and (2) post-exposure prophylaxis of disease following suspected or confirmed
Bacillus anthracis
exposure, when administered in conjunction with recommended antibacterial drugs. The efficacy of BioThrax
®
for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.
Select Important Safety Information
Contraindication : Severe allergic reaction (e.g., anaphylaxis) after a previous dose of BioThrax ® or a component of the vaccine. Warnings and Precautions : Latex : The stopper of the vial contains natural rubber latex and may cause allergic reactions in latex sensitive individuals. Pregnancy : Avoid use in pregnancy unless the potential benefit outweighs the potential risk to the fetus. Adverse Reactions: The most common (>10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, fatigue, and headache.
Please see the full Prescribing Information for BioThrax ® for additional safety information.
Disclaimer: The views and opinions expressed herein regarding any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply endorsement, recommendation, or favoring by the United States government and shall not be used for advertising or product endorsement purposes.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our
website
and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
